Abstracts tagged "human leukocyte antigens (HLA) and rheumatoid arthritis (RA)"

Abstract Number: 1976 • 2018 ACR/ARHP Annual Meeting
Sequencing of the MHC Region Defines HLA-DQA1 As Driven Risk for Anti-Citrullinated Protein Antibodies (ACPA)-Positive Rheumatoid Arthritis in Han Population
Jianping Guo¹, Tao Zhang², Hongzhi Cao², Xiaowei Li², Mengru Liu¹, Yundong Zou¹ and Zhan-Guo Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Beijing Genomics Institute (BGI)-Shenzhen, Shenzhen, China
Background/Purpose: The strong genetic contribution of the major histocompatibility complex (MHC) to rheumatoid arthritis (RA) susceptibility has been generally attributed to HLA-DRB1. However, due to…
Abstract Number: 2431 • 2017 ACR/ARHP Annual Meeting
Acquisition of Protective Alleles in Women with Rheumatoid Arthritis through Microchimerism
Sami B. Kanaan¹, Vijayakrishna K. Gadi^1,2, Alexandra M. Forsyth¹, Christine Luu¹, Tessa Aydelotte¹ and J. Lee Nelson^1,3, ¹Clinical Research Division, Fred Hutchinson Cancer Research Center, SEATTLE, WA, ²Division of Oncology, University of Washington, SEATTLE, WA, ³Division of Rheumatology, University of Washington, SEATTLE, WA
Background/Purpose: As in many autoimmune diseases, rheumatoid arthritis (RA) has a female predominance and strong genetic susceptibility from the HLA region. The shared epitope (SE),…
Abstract Number: 3121 • 2016 ACR/ARHP Annual Meeting
Specific Antibody Subphenotypes in Rheumatoid Arthritis Are Associated with Unique HLA-DRB1 Residues at Position 11
Chikashi Terao^1,2, Boel Brynedal³, Zuomei Chen⁴, Xia Jiang⁴, Helga Westerlind⁴, Monika Hansson⁵, Linda Mathsson-Alm^6,7, Per Johan Jakobsson⁸, Karl Skriner⁹, Guy Serre¹⁰, Johan Rönnelid⁷, Leonid Padyukov⁸, Jane Worthington¹¹, Lars Alfredsson⁴, Lars Klareskog⁸ and Soumya Raychaudhuri^1,2,11, ¹Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Program in Medical and Population Genetics, Broad Institute, Boston, MA, ³Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, ⁴Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ⁶Thermo Fisher Scientific, Uppsala, Sweden, ⁷Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, ⁸Unit of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁹Humboldt University of Berlin, Berlin, Germany, ¹⁰Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, ¹¹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Antibody to citrullinated peptides/proteins (ACPA) is specific feature of rheumatoid arthritis (RA) and seen in 50 to 70% of RA patients. Amino acid (AA)…
Abstract Number: 3074 • 2015 ACR/ARHP Annual Meeting
The Shared Rheumatoid Arthritis HLA-DRB1 Susceptibility Epitope Shapes the Molecular Orientation of Citrulline and the Autoreactive T Cell Receptor Repertoire
Jurgen van Heemst¹, Stephen Scally², Soi Cheng Law³, Diane van der Woude⁴, Carol Hitchon⁵, David B. Robinson⁶, T. W. J. Huizinga⁷, Hugh H Reid⁸, René E. M. Toes⁷, Hani El-Gabalawy⁹, Jamie Rossjohn¹⁰ and Ranjeny Thomas¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Monash University, Melbourne, Australia, ³The University of Queensland Diamantina Institute, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Australia, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Melbourne, Australia, ⁹University of Manitoba Arthritis Center, Winnipeg, MB, Canada, ¹⁰Institute of Infection and Immunity, Cardiff University, School of Medicine, Heath Park, Cardiff, England, ¹¹Translational Research Institute, The University of Queensland Diamantina Institute, Brisbane, Australia
Background/Purpose: Large-scale genomic studies have identified many genetic associations with autoimmune diseases, but the precise pathogenetic mechanisms by which the associated genes impact disease susceptibility…
Abstract Number: 1476 • 2014 ACR/ARHP Annual Meeting
A Dose Response Relationship Between Shared Epitope and ACPA Level: But Not All SE Alleles Are Created Equal
Jeremy Sokolove¹, Lauren J. Lahey¹, Catriona Wagner², Irene Smolik³, David B. Robinson⁴, Elizabeth D. Ferucci⁵, Marianna Newkirk⁶, Marvin Fritzler⁷, William H. Robinson⁸ and Hani El-Gabalawy⁹, ¹VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ²VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁵Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ⁶McGill University, Montreal, QC, Canada, ⁷Medicine, University of Calgary, Calgary, AB, Canada, ⁸VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Indigenous North American populations have high prevalence of seropositive RA. The Cree/Ojibway population in Central Canada and the Alaska Native population have a high prevalence…
Abstract Number: 808 • 2013 ACR/ARHP Annual Meeting
A Genome Wide Association Study Of Rheumatoid Arthritis Without Antibodies Against Citrullinated Peptides
Lara Bossini-Castillo¹, Carolien de Kovel², Henrik Kallberg³, Marieke J.H. Coenen⁴, Paul P. Tak⁵, Marcel D. Posthumus⁶, Cisca Wijmenga⁷, Thomas W.J. Huizinga⁸, Annette H.M. van der Helm-van Mil⁹, Luis Rodriguez-Rodriguez¹⁰, Isidoro Gonzalez-Alvaro¹¹, Miguel Angel Gonzalez-Gay¹², Irene E. van der Horst-Bruinsma¹³, B.a.C Dijkmans¹⁴, G. J. Wolbink¹⁵, Roel A. Ophoff², Piet L.C.M. van Riel¹⁶, Lars Klareskog³, J.B.a. Crusius¹⁷, Elisabeth Brouwer¹⁸, Javier Martin¹⁹, Niek de Vries⁵, René E.M. Toes⁹, Leonid Padyukov²⁰ and Bobby P.C. Koeleman²¹, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Granada, Spain, ²Department of Medical Genetics, UMCU Utrecht, Utrecht, Netherlands, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Rheumatology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁷Department of Genetics, University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰Hospital Clínico San Carlos, Department of Rheumatology, Madrid, Spain, ¹¹Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ¹²Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, ¹³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ¹⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁷Pathology, VU University Medical Center, Amsterdam, Netherlands, ¹⁸Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ¹⁹Immunology, Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, ²⁰Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ²¹Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a common autoimmune disease that is associated with a progressive loss of the joints induced by a chronic inflammation of…
Abstract Number: 1210 • 2012 ACR/ARHP Annual Meeting
Effect of HLA-DRB1*0901 Suggest Distinctive Mechanisms of Rheumatoid Arthritis Susceptibility
So-Young Bang¹, Hye-Soon Lee², Kyung Wha Lee³ and Sang-Cheol Bae⁴, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ³Hallym Institute for Genome Application,Hallym University Sacred Heart Hospital, Anyang, South Korea, ⁴Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Although HLA-DRB1 shared epitope (SE) alleles and DRB1*0901 have repeatedly been shown to be associated with RA susceptibility, the effect of each allele on…
Abstract Number: 976 • 2012 ACR/ARHP Annual Meeting
Effect of Interactions Between Validated Rheumatoid Arthritis Genetic Factors and Environmental Factors On Rheumatoid Arthritis Risk
Chia-Yen Chen¹, Linda T. Hiraki², Susan Malspeis³, Jing Cui⁴, Bing Lu⁴, Robert M. Plenge⁵, Karen H. Costenbader⁴ and Elizabeth W. Karlson⁶, ¹Department of Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Studies have shown associations between environmental factors and rheumatoid arthritis (RA) risk. Also, genome-wide association studies (GWAS) have identified genetic markers associated with RA…
Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Heidi Kokkonen¹, Mikael Brink², Monika Hansson³, Linda Mathsson⁴, Ewa Lassen⁵, Per Johan Jakobsson⁶, Rikard Holmdahl⁷, Johan Rönnelid⁴, Lars Klareskog⁸ and Solbritt M. Rantapaa-Dahlqvist⁹, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁵Transfusional Medicin, Umeå University, Umeå, Sweden, ⁶Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁸Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁹Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…
Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis
Lisbeth Arlestig¹, Mikael Brink², Monika Hansson³, Per Johan Jakobsson⁴, Rikard Holmdahl⁵, Linda Mathsson⁶, Johan Ronnelid⁶, Lars Klareskog⁷ and Solbritt M. Rantapaa-Dahlqvist⁸, ¹Rheumatology, Umeå University, Umea, Sweden, ²Umea University, Umea, Sweden, ³Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, ⁶Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁸Rheumatology, Institution of Public health and clinical medicine/ Rheumatology, University of Umeå, Umeå, Sweden, Umea, Sweden
Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].